<DOC>
	<DOCNO>NCT01039883</DOCNO>
	<brief_summary>The purpose study determine whether albaconazole tablet albaconazole capsule ( single 400mg dose ) act body way period time .</brief_summary>
	<brief_title>A Study Compare Blood Levels Albaconazole Healthy Subjects Who Have Received Single Dose 400 mg Albaconazole Tablet Versus Albaconazole Capsule</brief_title>
	<detailed_description>The aim study compare bioavailability formulation use earlier clinical study ( albaconazole capsule ) formulation intend use development ( albaconazole tablet ) . The study also design assess safety tolerability single oral dose albaconazole tablet ( 400 mg ) , assess bioequivalence albaconazole tablet albaconazole capsule .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<criteria>Capable understand willing provide sign dated write voluntary inform consent ( local national authorization requirement ) protocol specific procedure perform . Male female age 18 45 year time consent time first dose . A body mass index ( BMI ) 18.5 30 kg/m2 . Able complete study comply study instruction . Free clinically significant disease determine history , physical examination , laboratory testing . The subject nonsmoker exsmoker . If subject ex smoker , he/she must use nicotine least 6 month first dose . The screen baseline laboratory parameter must within normal range unless agree clinically relevant principal investigator sponsor . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase , total bilirubin value low 1.5 time upper normal limit screening . The subject negative result follow test screen : Hepatitis B surface antigen ( HBsAg ) Hepatitis B core antibody ( HBcAc ) Antihepatitis C virus ( AntiHCV ) Human immunodeficiency virus ( HIV ) antibody test Urine drug screen Sexually active female childbearing potential participating study must agree use medically acceptable method contraception receive protocolassigned product 30 day follow last dose study product . A woman childbearing potential define one biologically capable become pregnant ; include perimenopausal woman le 2 year last menses . Acceptable contraceptive method include follow : Hormonal contraception , include oral , injectable , implantable method start least 2 month prior screen . If hormonal contraception start less 2 month prior screen , form nonhormonal contraception add third continuous month hormonal contraception complete . Two form reliable nonhormonal contraception , include use either intrauterine device plus reliable barrier method 2 reliable barrier method . Reliable barrier method include condom diaphragms . A cervical cap also reliable barrier method , provide female subject never give birth naturally . The combined use condom spermicide constitute 2 form acceptable nonhormonal contraception , provide use properly . The use spermicide alone improper use condom inferior method contraception . Subjects surgical sterilization , include tubal sterilization partner 's vasectomy , must use form nonhormonal contraception . A barrier method sterilization plus spermatocide acceptable . Women currently sexually active must agree use medically accept method contraception become sexually active participate study . Male subject and/or partner must use medically acceptable form contraception Female pregnant ( positive pregnancy test ) , try become pregnant , breast feeding . Received investigational drug within 30 day study day 1 schedule receive investigational drug study product study . Used prescription drug therapy , counter ( nonprescription ) medication , recreational drug , herbal product within 30 day dose , unless agree clinically relevant principal investigator sponsor . Participated previous study study product . Currently use medication , opinion investigator , may affect evaluation study product place subject undue risk . Currently suffer disease condition , opinion investigator , may affect evaluation study product place subject undue risk . Has history anemia , iron deficiency , iron depletion . Has history condition possibly affect absorption drug ( eg , peptic ulcer disease , gastrectomy , intestinal malabsorption ) . Considered immunocompromised . History drug , prescription medicine , alcohol abuse within past 2 year . Has history know suspected intolerance ingredient study product . Has know drug allergy . Has clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , hematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Intends donate blood blood component receive study product duration pharmacokinetic sampling period . Has donate blood significant blood loss ( ≥250 mL ) within 30 day dose donated plasma within 7 day dose . Has QT interval correct heart rate ( Fridericia 's correction formula ) ( QTcF ) &gt; 450 m ECG abnormality except follow : Mild sinus bradycardia young , athletic subject ( heart rate 46 beat per minute allow ) . Mild sinus arrhythmia . Mild first degree atrioventricular ( AV ) block ( PR interval &lt; 0.23 sec ) . Mild right leave axis deviation . Incomplete right bundle branch block . Isolated leave anterior fascicular block ( leave anterior hemiblock ) young , athletic subject . Early repolarization . Uncorrected QT interval QT interval correct heart rate Bazett 's correction formula ( QTcB ) exceed 450 m , QTcF ≤450 m . Considered unable unlikely attend necessary visit . Employees investigator/ clinical research organization Stiefel involve study , immediate family member ( partner , offspring , parent , sibling , sibling 's offspring ) employee involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>